

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Lee's Pharmaceutical Holdings Limited**

**李氏大藥廠控股有限公司\***

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 950)**

### **VOLUNTARY ANNOUNCEMENT – UPDATE ON AN INVESTIGATIONAL ONCOLOGY PRODUCT**

This announcement is made by the board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that, on 25 May 2018, the Group has been granted the approval for conducting clinical trials for TG02, a novel oral pyrimidine-based multi-kinase inhibitor, by the China Food and Drug Administration (“**CFDA**”).

TG02 was licensed in by the Group from Tragara Pharmaceuticals Inc. (“**Tragara**”) and several phase I clinical trials has been performed in the United States. The coming phase I clinical trial in China will be a 3+3 design with the starting dose of 200 mg regimens to determine the Maximum Tolerated Dose (“**MTD**”) in Chinese Glioblastoma (“**GBM**”) patients. Clinical data from this study could be available by the end of the year 2019, and the positive results could lead to the following phase II and III trial in China.

TG02 is a multi-kinase inhibitor with the primary effect on CDK9 activity, inhibiting transcriptional progress. TG02 has been investigated preclinically and clinically in hematologic malignancy and gliomas. Preliminary results demonstrated anti-glioma effects and good blood brain barrier penetration. Temozolomide (TMZ) is the current first line treatment for GBM, but is limited by resistant mechanisms. Our preclinical studies have demonstrated the anti-glioma effects of TG02 and the synergy with TMZ through modulation of transcription and metabolism. A phase I trial of TG02 plus dose-dense or metronomic TMZ for adults with recurrent anaplastic astrocytoma and GBM is currently performing in the United States. The up to date results show that TG02 and TMZ are generally well-tolerated in combination in recurrent high grade gliomas. The safety and preliminary efficacy analysis suggest that the combination of TG02 and TMZ is a promising therapy in refractory high grade astrocytomas.

The Group is aiming for initiation of the study in the second half of 2018. Indeed, combination of different oncological drugs will be the Group's focus, following the phase I TG02 trials, its combination effects with other oncological drugs in our pipeline such as the anti-PDL1 monoclonal antibody ZKAB001 will be initiated.

According to the data of IMS Health (“IMS”), the global spending on cancer medications amounted to US\$100 billion in 2014, much higher than the spending on medications for other diseases, and is expected to rise to US\$150 billion in 2020. GBM is the most common form of brain cancer in adults, and the most deadly. As an extremely aggressive cancer, GBM invades throughout the brain and damages critical neural functions. Only 5% of GBM patients will survive 5 years after diagnosis and half of patients will only survive 15 or fewer months. New treatments for GBM are desperately needed. WHO estimates that the incidence of GBM worldwide is 2-3 people per 100,000 people, which means that the burden in China could exceed 40,000 cases per year.

The Group is fully integrated with solid infrastructures in drug development, clinic, perspectives and the Group has established extensive partnerships with over 20 international companies and currently markets 17 proprietary and licensed-in pharmaceutical products in Mainland China, Hong Kong and Macau. the Group focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology, ophthalmology and others. The Group has more than 50 products under different development stages stemming from both internal research and development as well as from the recent acquisition of licensing and distribution rights from various United States, European and Japanese companies.

Tragara is a privately held pharmaceutical company based in Carlsbad, California. Tragara is focused on the clinical and commercial development of proprietary medicines for the treatment of cancer. Tragara's lead candidate, TG02, is currently in phase Ib development for gliomas. Tragara is managed by a team of entrepreneurs with big pharma and small biotech experience in the development and commercialisation of oncology therapeutics. Its investors include: Domain Associates, Lee's Healthcare Industry Fund, LPE II, Morgenthaler Ventures, ProQuest Investments, and RusnanoMedInvest. Tragara strives to provide much-needed therapies that will contribute to patient health through better survival and an increase in the quality of life. Additional information is available at <http://www.tragarapharma.com>.

By order of the Board of  
**Lee's Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 14 June 2018

*\* For identification purpose only*

*As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.*